Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia

Molecular Psychiatry

Volumn 8, Issue 6, 2003, Pages 592-610

  Weickert, C S ^a,b   Hyde, T M ^a   Lipska, B K ^a   Herman, M M ^a   Weinberger, D R ^a   Kleinman, J E ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b MSC 1385 ^*  (United States)

Author keywords

BDNF; DLPFC; Growth factor; Neurotrophin; Post mortem; TrkB ligand

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; LIGAND; MESSENGER RNA; NEUROTROPHIN; RNA; TRKB LIGAND; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOPSY; BRAIN CELL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DENDRITIC SPINE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; METABOLISM; NORTHERN BLOTTING; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN ISOLATION; PYRAMIDAL NERVE CELL; RIBONUCLEASE PROTECTION ASSAY; SCHIZOPHRENIA; SENSORY NERVE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; COHORT STUDIES; FEMALE; GLUTAMIC ACID; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PREFRONTAL CORTEX; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 0041847014     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001308     Document Type: Article

References (131)

1. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 1989; 341: 149-152.
2. Lewin GR. Neurotrophins and the specification of neuronal phenotype. Philos Trans R Soc London B Biol Sci 1996; 351: 405-411.
3. Maisonpierre PC, Le Beau MM, Espinosa III R, Ip NY, Belluscio L, de la Monte SM et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991; 10: 558-568.
4. Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci 1995; 18: 223-253.
5. Ghosh A, Carnahan J, Greenberg ME. Requirement for BDNF in activity-dependent survival of cortical neurons. Science 1994; 263: 1618-1623.
6. Lindholm D, Dechant G, Heisenberg CP, Thoenen H. Brain-derived neurotrophic factor is a survival factor for cultured rat cerebellar granule neurons and protects them against glutamate-induced neurotoxicity. EuryNeurosci 1993; 5: 1455-1464.
7. Cheng B, Mattson MP. NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults. Brain Res 1994; 640: 56-67.
8. McAllister AK, Katz LC, Lo DC. Neurotrophin regulation of cortical dendritic growth requires activity. Neuron 1996; 17: 1057-1064.
9. McAllister AK, Lo DC, Katz LC. Neurotrophins regulate dendritic growth in developing visual cortex. Neuron 1995; 15: 791-803.
10. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995; 270: 593-598.
11. Kang H, Schuman EM. Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 1995; 267: 1658-62.
12. Zafra F, Hengerer B, Leibrock J, Thoenen H, Lindholm D. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J 1990; 9: 3545-50.
13. Gwag BJ, Springer JE. Activation of NMDA receptors increases brain-derived neurotrophic factor BDNF mRNA expression in the hippocampal formation. Neuroreport 1993; 5: 125-128.
14. Friedman WJ, Ernfors P, Persson H. Transient and persistent expression of NT-3/BDNF mRNA in the rat brain during postnatal development. J Neurosci 1991; 11: 1577-1584.
15. Maisonpierre PC, Belluscio L, Friedman B, Alderson RF, Wiegand SJ, Furth ME et al. NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 1990; 5: 501-509.
16. Dugich-Djordjevic MM, Tocco G, Willoughby DA, Najm I, Pasinetti G, Thompson RF et al. BDNF mRNA expression in the developing rat brain following kainic acid-induced seizure activity. Neuron 1992; 8: 1127-1138.
17. Ringstedt T, Lagercrantz H, Persson H. Expression of members of the trk family in the developing postnatal rat brain. Brain Res Dev Brain Res 1993; 72: 119-131.
18. Knusel B, Rabin SJ, Hefti F, Kaplan DR. Regulated neurotrophin receptor responsiveness during neuronal migration and early differentiation. J Neurosci 1994; 14: 1542-1554.
19. Katoh-Semba R, Takeuchi I K, Semba R, Kato K. Distribution of brain-derived neurotrophic factor in rats and its changes with development in the brain. J Neurochem 1997; 69: 34-42.
20. Itami C, Mizuno K, Kohno T, Nakamura S. Brain-derived neurotrophic factor requirement for activity-dependent maturation of glutamatergic synapse in developing mouse somatosensory cortex. Brain Res 2000; 857: 141-150.
21. Weickert CS, Kleinman JE. The neuroanatomy and neurochemistry of schizophrenia. Psychiatr Clin North Am 1998; 21: 57-75.
22. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995; 52: 829-836.
23. Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA et al. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 1998; 43: 641-648.
24. Bertolino A Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 1996; 153: 1554-1563.
25. Block W, Bayer TA, Tepest R, Traber F, Rietschel M, Muller D et al. Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study. Neurosci Lett 2000; 289: 147-151.
26. Mimics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000; 28: 53-67.
27. Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia. Schizophr Res 2002; 58: 11-20.
28. Weickert CS, Webster MJ, Hyde TM, Herman MM, Bachus SE, Bali G et al. Reduced GAP-43 mRNA in dorsolateral prefrontal cortex of patients with schizophrenia. Cerebr Cortex 2001; 11: 136-147.
29. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry 1997; 54: 660-669.
30. Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ et al. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience 1999; 91: 1247-1255.
31. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WS et al. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. Mol Psychiatry 1999; 4: 39-45.
32. Thompson PM, Sower AC, Perrone-Bizzozero NI. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biol Psychiatry 1998; 43: 239-243.
33. Glantz LA, Lewis DA. Dendritic spine density in schizophrenia and depression. Arch Gen Psychiatry 2001; 58: 203.
34. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer A et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neural Neurosurg Psychiatry 1998; 65: 446-453.
35. Rajkowska G, Selemon LD, Goldman-Rakic PS. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 1998; 55: 215-224.
36. Pierri JN, Volk CL, Auh S, Sampson A, Lewis DA. Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry 2001; 58: 466-473.
37. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995; 52: 805-818; discussion 819-820.
38. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional stereologic counting method. J Comp Neural 1998; 392: 402-412.
39. Harrison PJ, Eastwood SL. Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocompus 2001; 11: 508-519.
40. Heckers S, Konradi C. Hippocampal neurons in schizophrenia. J Neural Transm 2002; 109: 891-905.
41. Weickert CS, Weinberger DR. A candidate molecule approach to defining developmental pathology in schizophrenia. Schizophr Bull 1998; 24: 303-316.
42. Causing CG, Gloster A, Aloyz R, Bamji SX, Chang E, Fawcett J et al. Synaptic innervation density is regulated by neuron-derived BDNF. Neuron 1997; 18: 257-267.
43. Wetmore C, Ernfors P, Persson H, Olson L. Localization of brain-derived neurotrophic factor mRNA to neurons in the brain by in situ hybridization. Exp Neurol 1990; 109: 141-152.
44. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991; 7: 695-702.
45. Lipska BK, Khaing ZZ, Weickert CS, Weinberger DR. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 2001; 14: 135-144.
46. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA, Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 1990; 9: 2459-2464.
47. Huntley GW, Benson DL, Jones EG, Isackson PJ. Developmental expression of brain derived neurotrophic factor mRNA by neurons of fetal and adult monkey prefrontal cortex. Brain Res Dev Brain Res 1992; 70: 53-63.
48. Kleinman JE, Hyde TM, Herman MM. In: Bloom FE and Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press Ltd: New York, 1995, pp 859-864.
49. Rajkowska G, Goldman-Rakic PS. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cerebr Cortex 1995: 5: 307-322.
50. Torrey EF. In: Surviving Schizophrenia. Harper & Row: New York, 1983, p 188.
51. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1989.
52. Lazar LM, Blum M. Regional distribution and developmental expression of epidermal growth factor and transforming growth factor-alpha mRNA in mouse brain by a quantitative nuclease protection assay. J Neurosci 1992; 12: 1688-1697.
53. Friedman WJ, Black IB, Kaplan DR. Distribution of the neurotrophins brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 in the postnatal rat brain: an immunocytochemical study. Neuroscience 1998; 84: 101-114.
54. Whitfield Jr HJ, Brady LS, Smith MA, Mamalakl E, Fox RJ, Kerkenham M et al. Optimization of cRNA probe in situ hybridization methodology for localization of glucocorticoid receptor mRNA in rat brain: a detailed protocol. Cell Mol Neurobiol 1990; 10: 145-157.
55. Hayashi M, Yamashita A, Shimizu K. Somatostatin and brain-derived neurotrophic factor mRNA expression in the primate brain: decreased levels of mRNAs during aging. Brain Res 1997; 283-289.
56. Tokuyama W, Okuno H, Hashimoto T, Xin Li Y, Miyashita Y. BDNF upregulation during declarative memory formation in monkey inferior temporal cortex. Nat Neurosci 2000; 3: 1134-1142.
57. Hashimoto T, Okuno H, Tokuyama W, Li YX, Miyashita Y. Expression of brain-derived neurotrophic factor, neurotrophin-3 and their receptor messenger RNAs in monkey rhinal cortex. Neuroscience 2000; 95: 1003-1010.
58. Gorba T, Wahle P. Expression of TrkB and TrkC but not BDNF mRNA in neurochemically identified interneurons in rat visual cortex in vivo and in organotypic cultures. Eur J Neurosci 1999; 11: 1179-1190.
59. Linden AM, Vaisanen J, Lakso M, Nawa H, Wong G, Castren E et al. Expression of neurotrophins BDNF and NT-3 and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J Mol Neurosci 2000; 14: 27-37.
60. Angelucci F, Aloe L, Vasquez PJ, Mathe AA. Mapping the differences in the brain concentration of brain-derived neurotrophic factor BDNF and nerve growth factor NGF in an animal model of depression. Neuroreport 2000; 11: 1369-1373.
61. Dawson NM, Hamid EH, Egan MF, Meredith GE. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 2001; 39: 70-81.
62. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000; 5: 293-300.
63. Cabelli RJ, Shelton DL, Segal RA, Shatz CJ. Blockade of endogenous ligands of trkB inhibits formation of ocular dominance columns. Neuron 1997; 19: 63-76.
64. Linnarsson S, Bjorklund A, Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci 1997; 9: 2581-2587.
65. Mu JS, Li WP, Yao ZB, Zhou XF. Deprivation of endogenous brain-derived neurotrophic factor results in impairment of spatial learning and memory in adult rats. Brain Res 1999; 835: 259-265.
66. Mizuno M, Yamada K, Olariu A, Nawa H, Nabeshima T. Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. J Neurasci 2000; 20: 7116-7121.
67. Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M et al. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron 1993; 10: 475-489.
68. Timmusk T, Metsis M. Regulation of BDNF promoters in the rat hippocampus. Neurochem Int 1994; 25: 11-15.
69. Timmusk T, Belluardo N, Persson H, Metsis M. Developmental regulation of brain-derived neurotrophic factor messenger RNAs transcribed from different promoters in the rat brain. Neuroscience 1994; 60: 287-291.
70. Nanda S, Mack KJ. Multiple promoters direct stimulus and temporal specific expression of brain-derived neurotrophic factor in the somatosensory cortex. Brain Res Mol Brain Res 1998; 62: 216-219.
71. Nakayama M, Gahara Y, Kitamura T, Ohara O. Distinctive four promoters collectively direct expression of brain-derived neurotrophic factor gene. Brain Res Mol Brain Res 1994; 21: 206-218.
72. Kokaia Z, Metsis M, Kokaia M, Bengzon J, Elmer E, Smith ML et al. Brain insults in rats induce increased expression of the BDNF gene through differential use of multiple promoters. Eur J Neurosci 1994; 6: 587-596.
73. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-3261.
74. Vaidya VA, Duman RS. Depression - emerging insights from neurobiology. Br Med Bull 2001; 57: 61-79.
75. Duman RS. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998; 44: 324-335.
76. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265.
77. Sasaki T, Dai XY, Kuwata S, Fukuda R, Kunugi H, Hattori M et al. Brain-derived neurotrophic factor gene and schizophrenia in Japanese subjects. Am J Med Genet 1997; 74: 443-444.
78. Hawi Z, Straub RE, O'Neill A, Kendler KS, Walsh D, Gill M et al. No linkage or linkage disequilibrium between brain-derived neurotrophic factor BDNF dinucleotide repeat polymorphism and schizophrenia in Irish families. Psychiatry Res 1998; 81: 111-116.
79. Wassink TH, Nelson JJ, Crowe RR, Andreasen NC. Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. Am J Med Genet 1999; 88: 724-728.
80. Krebs MO, Guillin O, Bourdell MC, Schwartz JC, Olie JP, Poirier MF et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 2000; 5: 558-562.
81. Virgos C, Martorell L, Valero J, Figuera L, Civeira F, Joven J et al. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res 2001; 49: 65-71.
82. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A et al. A common mutation in the BDNF gene affects regulated secretion of BDNF, human memory and hippocampal function. Cell 2003; 112: 1-20.
83. Altar CA, Boylan CB, Fritsche M, Jackson C, Hyman C, Lindsay RM et al. The neurotrophins NT-4/5 and BDNF augment serotonin dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra. Exp Neurol 1994; 130: 31-40.
84. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Psychological Assessment Resources Inc., 1993, pp 26-27.
85. Webster MJ, Weickert CS, Herman MM, Kleinman JE. BDNF mRNA expression during the postnatal development maturation and aging of the human prefrontal cortex. Brain Res Dev Brain Res 2002; 139: 139-150.
86. Romanczyk TB, Weickert CS, Webster MJ, Herman MM, Akil M, Kleinman JE et al. Alterations in trkB mRNA in the human prefrontal cortex throughout the lifespan. Eur J Neurosci 2002; 15: 269-280.
87. Woo TU, Pucak ML, Kye CH, Matus CV, Lewis DA. Peripubertal refinement of the intrinsic and associational circuitry in monkey prefrontal cortex. Neuroscience 1997; 80: 1149-1158.
88. Rosenberg DR, Lewis DA. Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: a tyrosine hydroxylase immunohistochemical analysis. J Comp Neurol 1995; 358: 383-400.
89. Bourgeois JP, Goldman-Rakic PS, Rakic P. Synaptogenesis in the prefrontal cortex of rhesus monkeys. Cerebr Cortex 1994; 4: 78-96.
90. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K et al. The early stages of schizophrenia: speculations on the pathogenesis, pathophysiology, and therapeutic approaches Biol Psychiatry 2001; 50: 884-897.
91. Molteni R, Lipska BK, Weinberger DR, Racagni G, Riva MA. Developmental and stress-related, changes of neurotrophic factor gene expression in an animal model of schizophrenia. Mol Psychiatry 2001; 6: 285-292.
92. Cheng B, Goodman Y, Begley JG, Mattson MP. Neurotrophin-4/5 protects hippocampal and cortical neurons against energy deprivation- and excitatory amino acid-induced injury. Brain Res 1994; 650: 331-335.
93. Seil FJ. BDNF and NT-4, but not NT-3, promote development of inhibitory synapses in the absence of neuronal activity. Brain Res 1999; 818: 561-564.
94. Mount HT, Dreyfus CF, Black IB. Neurotrophin-3 selectively increases cultured Purkinje cell survival. Neuroreport 1994; 5: 2497-2500.
95. Hyman C, Juhasz M, Jackson C, Wright P, Ip NY, Lindsay RM et al. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci 1994; 14: 335-347.
96. Larkfors L, Lindsay RM, Alderson RF. Characterization of the responses of Purkinje cells to neurotrophin treatment. J Neurochem 1996; 66: 1362-1373.
97. Spenger C, Hyman C, Studer L, Egli M, Evtouchenko L, Jackson C et al. Effects of BDNF on dopaminergic, serotonergic, and GABAergic neurons in cultures of human fetal ventral mesencephalon. Exp Neurol 1995; 133: 50-63.
98. Abe S, Suzuki T, Ito T, Baba A, Hori T, Kurita H et al. Differential expression of GABAA receptor subunit mRNAs and ligand binding sites in rat brain following phencyclidine administration. Synapse 2000; 38: 51-60.
99. Akbarian S, Huntsman MM, Kim JJ, Tafazzoli A, Potkin SG, Bunney Jr WE et al. GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cerebr Cortex 1995; 5: 550-560.
100. Benes F M, Vincent S L, Marie A, Khan Y. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 1996; 75: 1021-1031.
101. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 1997; 24: 349-355.
102. Beasley C, Zhang Z, Patten I, Reynolds G. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 2002; 52: 708.
103. Lewis DA. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Brain Res Rev 2000; 31: 270-276.
104. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci USA 1998; 95: 5341-5346.
105. Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA et al. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cerebr Cortex 2002; 12: 1063-1070.
106. Ventimiglia R, Mather PE, Jones BE, Lindsay RM. The neuroBDNF, NT-3 and NT-4/5 promote survival and morphotrophins logical and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci 1995; 7: 213-222.
107. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997; 389: 856-860.
108. Ivkovic S, Ehrlich ME. Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci 1999; 19: 5409-5419.
109. Mizuno K, Carnahan J, Nawa H. Brain-derived neurotraphic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994; 165: 243-256.
110. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-498.
111. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991; 350: 230-232.
112. Zhou J, Bradford HF, Stern GM. The response of human and rat fetal ventral mesencephalon in culture to the brain-derived neurotrophic factor treatment. Brain Res 1994; 656: 147-156.
113. Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 1999; 156: 1580-1589.
114. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P et al. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001; 411: 86-89.
115. Dluzen DE, Gao X, Story GM, Anderson LI, Kucera J, Walro JM et al. Alterations in nigrostriatal dopaminergic function within BDNF mutant mice. Exp Neurol 1999; 160: 500-507.
116. Dluzen DE et al. Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice. Exp Neurol 2001; 170: 121-128.
117. Dluzen DE, Anderson LI, McDermott JL, Kucera J, Walro JM. Striatal dopamine output is compromised within +/- BDNF mice. Synapse 2002; 43: 112-117.
118. Narisawa-Saito M, Carnahan J, Araki K, Yamaguchi T, Nawa H. Brain-derived neurotrophic factor regulates the expression of AMPA receptor proteins in neocortical neurons. Neuroscience 1999; 88: 1009-1014.
119. Eastwood SL, Kerwin RW, Harrison PJ. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry 1997; 41: 636-643.
120. Noga JT, Hyde TM, Herman MM, Spurney CF, Bigelow LB, Weinberger DR et al. Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains. Synapse 1997; 27: 168-176.
121. Thakker-Varia S, Alder J, Crozier RA, Plummer MR, Black IB. Rab3A is required for brain-derived neurotrophic factor-induced synaptic plasticity: transcriptional analysis at the population and single-cell levels. J Neurosci 2001; 21: 6782-6790.
122. Blennow K, Bogdanovic N, Heilig M, Grenfeldt B, Karlsson I, Davidsson P et al. Reduction of the synaptic protein rab3a in the thalamus and connecting brain regions in post-mortem schizophrenic brains. J Neural Transm 2000; 107: 1085-1097.
123. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 1990; 47: 1023-1028.
124. Pakkenberg B. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics. Schizophr Res 1992; 7: 95-100.
125. Popken GJ, Bunney Jr WE, Potkin SG, Jones EG. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc Natl Acad Sci USA 2000; 97: 9276-9280.
126. Byne W, Buchsbaum MS, Mattiace LA, Hazlett EA, Kemether E, Elhakem SL et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry 2002; 159: 59-65.
127. Young KA, Manaye KF, Liang C, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry 2000; 47: 944-953.
128. Spalding KL, Tan MM, Hendry IA, Harvey AR. Anterograde transport and trophic actions of BDNF and NT-4/5 in the developing rat visual system. Mol Cell Neurosci 2002; 19: 485-500.
129. Lotto RB, Asavaritikrai P, Vali L, Price DJ. Target-derived neurotrophic factors regulate the death of developing forebrain neurons after a change in their trophic requirements. J Neurosci 2001; 21: 3904-3910.
130. Lewis DA, Cruz DA, Melchitzky DS, Pierri JN. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. Am J Psychiatry 2001; 158: 1411-1422.
131. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001; 52: 79-86.